Search form

Search form

Scientists at Stanford University reported in the journal Cell Stem Cell that they were able to overcome immune system rejection of transplanted embryonic stem cells in mice after administering a short-term treatment with three co-stimulatory receptor blocking agents, drugs that "teach" T cells to accept transplanted cells. The finding might allow patients to receive donor cells without requiring them to use immunosuppressive drugs and might help prevent transplanted early-stage cells from turning into tumors.

Related Summaries

Astellas Pharma and Potenza Therapeutics entered into a collaboration to research and develop novel immuno-oncology treatments targeting checkpoint pathways, regulatory T cells and co-stimulatory signals. Under terms of the agreement, Astellas will conduct clinical studies and will be responsible for marketing products arising from the alliance, while Potenza will oversee drug discovery and provide Astellas with candidates for development. The agreement also includes an option for Astellas to acquire Potenza when the collaboration concludes.

Researchers from the University of Texas Southwestern Medical Center have developed a culture method that allowed for transplanted adult blood stem cells not to be attacked by the immune system. The cultured blood stem cells were successfully transplanted in mice, according to the study that was scheduled to be published Friday in Cell Stem Cell. The method could help prevent rejection of transplanted cells in patients with blood cancers, including leukemia, lymphoma and myeloma.

Researchers from the University of Texas Southwestern Medical Center have developed a culture method that allowed for transplanted adult blood stem cells not to be attacked by the immune system. The cultured blood stem cells were successfully transplanted in mice, according to the study scheduled to be published today in Cell Stem Cell. The method could help prevent rejection of transplanted cells in patients with blood cancers, including leukemia, lymphoma and myeloma.

The FDA and Allos Therapeutics settled on a design for a late-stage trial of Folotyn as first-line therapy for previously undiagnosed peripheral T-cell lymphoma. The drug was given accelerated approval in September 2009.

Scientists at Stanford University reported in the journal Cell Stem Cell that they were able to overcome immune system rejection of transplanted embryonic stem cells in mice after administering a short-term treatment with three co-stimulatory receptor blocking agents, drugs that "teach" T cells to accept transplanted cells. The finding might allow patients to receive donor cells without requiring them to use immunosuppressive drugs and might help prevent transplanted early-stage cells from turning into tumors.